Jerusalem, Israel based Brainsway finally won FDA clearance for its Deep TMS (transcranial magnetic stimulation) to be used for treatment of drug resistant depression.
The Brainsway system received a similar approval in Europe three years ago and is also being used there to control neuropathic chronic pain. Additionally, the technology is being trialed for a variety of conditions like Alzheimer’s and bipolar disorder, and even for smoking cessation (see flashbacks below).
More from Israel’s Globes business paper:
The company adds that the FDA approval for this indication is generally broader than the definition given by the company’s TMS device rival.
Brainsway said that the FDA certification of the Deep TMS device for use in the US for such a broad indication is further demonstration of the device’s efficacy and safety in treating depression, and could be an important milestone in changing the treatment for depression.
More from Globes: Israeli company Brainsway stock is jumping 26% after FDA approves device
Product page: Deep TMS H System…
Brainsway flashbacks on Medgadget: Brainsway’s Deep TMS EU Cleared for Neuropathic Chronic Pain; Brainsway’s Transcranial Magnetic Stimulation to Go on Trial for Bipolar Disorder; Transcranial Magnetic Stimulation Shows Initial Promise in Alzheimer’s Trial; Brainsway’s Transcranial Magnetic Stimulation Gets European Regulatory Approval for Treatment of Depression; Brainsway to Test TMS for Smoking Cessation; Positive Results Reported for Deep TMS H System For Depression; Deep TMS Technology by Brainsway;VA to Trial Transcranial Magnetic Stimulation for ADD
